Drugs › Nuclear export inhibitor
Brand name · Selinexor
Xpovio: adverse event reports filed with FDA
4,528 reports list it as a suspect or interacting product, 2019–2026. Class: Nuclear export inhibitor.
- 4,528
- reports as suspect product
- 0% of all reports · about 647 a year
- 27
- reports, 12 months to June 2026
- 464 in the 12 months before
- 42.5%
- marked serious by the reporter
- 54.3% across the class
- 16.5%
- record death among outcomes, as reported
- 748 reports · not verified by FDA
4,528 adverse event reports received by FDA list the brand name Xpovio (selinexor) as a suspect or interacting product, from July 2019 to June 2026. A further 276 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 27 reports listed it, down 94% from 464 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 647 reports a year and 0% of the 20,646,523 reports in the database, and 55.6% of the reports for the nuclear export inhibitor class. How many people take it is not in the data, so a count is not a rate of occurrence.
The MedDRA terms listed most often are nausea (42.7%), fatigue (32.7%) and decreased appetite (24.4%). A report can list several reactions, so shares add to more than 100%; 491 different terms appear across these reports. Nausea is recorded in 42.7% of these reports, a larger share than in the median nuclear export inhibitor drug (29.8%).
42.5% of the reports are marked serious by the reporter (54.3% across the class); 16.5% record death among the outcomes and 25.7% record hospitalisation, as reported. 80.9% of the reports came from consumers, and the largest patient age group is 65 to 74 (2.5%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Xpovio reports recording the termmedian drug in nuclear export inhibitor
- Nauseafeeling sick42.7%1,934
- Fatiguetiredness32.7%1,479
- Decreased appetitereduced appetite24.4%1,107
- Diarrhoealoose or frequent stools21.9%993
- Astheniaweakness or lack of energy15.2%689
- Vomitingbeing sick15%680
- Deaththe patient died; cause not stated by this term14.1%639
- Plasma cell myeloma11.8%533
- Weight decreasedweight loss11.4%515
- Platelet count decreasedlow platelet count10.8%487
- Dizzinesslight-headedness or unsteadiness8.2%371
- Constipationconstipation7.6%344
- Thrombocytopenialow platelets7.5%339
- Off label useused for a purpose or in a way not on the label6.3%287
- Anaemialow red blood cells5.9%267
- Drug ineffectivethe medicine did not work as expected5.7%260
- Dehydrationdehydration5.4%244
- White blood cell count decreasedlow white cell count5%228
- Dyspnoeashortness of breath4.9%220
- Falla fall4.8%219
- Pneumonialung infection4.6%209
- Confusional stateconfusion4.2%189
- Haemoglobin decreasedlow haemoglobin4.1%187
- Headachehead pain4.1%185
- Product dose omission issuea dose was missed4%179
- Somnolencedrowsiness3.5%160
- Insomniadifficulty sleeping3.5%159
- Pyrexiafever3.3%148
- Abdominal discomfortstomach discomfort3%138
- Malaisegeneral feeling of being unwell2.9%133
Top 30 of 491 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 2 drugs in the nuclear export inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 8,145 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 94.3% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Plasma cell myeloma | 3,556 | 78.5% |
| Diffuse large b-cell lymphoma | 143 | 3.2% |
| Brain neoplasm malignant | 116 | 2.6% |
| Plasma cell myeloma refractory | 36 | 0.8% |
| Malignant neoplasm of unknown primary site | 15 | 0.3% |
| Non-hodgkin's lymphoma | 14 | 0.3% |
The indication field is filled in by the reporter and is often blank; shares are of all 4,528 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Xpovio reports |
|---|---|---|
| Dexamethasone | 2,237 | 49.4% |
| Zofran | 1,017 | 22.5% |
| Acyclovir | 1,014 | 22.4% |
| Ondansetron | 920 | 20.3% |
| Olanzapine | 579 | 12.8% |
| Pomalyst | 480 | 10.6% |
| Gabapentin | 472 | 10.4% |
| Prochlorperazine | 392 | 8.7% |
| Aspirin | 390 | 8.6% |
| Velcade | 351 | 7.8% |
Other products listed in reports where Xpovio is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Xpovio | Nuclear export inhibitor | All reports |
|---|---|---|---|
| Reports as suspect product | 4,528 | 8,145 | 20,646,523 |
| Share of that pool | — | 55.6% | 0% |
| Reports, latest 12 months | 27 | — | 1,332,454 |
| Marked serious | 42.5% | 54.3% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 165 | 170 | 91 |
| Hospitalisation recorded, per 1,000 reports | 257 | 311 | 213 |
| Consumer-filed share | 80.9% | 55.8% | 45.8% |
| Top term, share of reports | Nausea 42.7% | median 29.8% | 3.8% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the nuclear export inhibitor class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Selinexor | generic | 3,617 | 920 | 69.1% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Xpovio reports
How many adverse event reports has FDA received for Xpovio?
4,528 reports list Xpovio as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 27 of them arrived in the latest 12 months. Another 276 list it only as a concomitant medication.
What reactions are recorded in Xpovio reports?
nausea (42.7%), fatigue (32.7%), decreased appetite (24.4%), diarrhoea (21.9%) and asthenia (15.2%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Xpovio was responsible.
How serious are the reports?
42.5% are marked serious by the reporter. Among the outcomes recorded, 16.5% of reports include death and 25.7% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (80.9%), other health professional (10.2%) and physician (6.1%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Xpovio rising?
27 reports in the 12 months to June 2026, down 94% from 464 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Xpovio was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Xpovio?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Xpovio as a suspect or interacting product; reports listing it only as a concomitant medication (276) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.